Abstract |
Sixty-three consecutive patients with small cell carcinoma of the lung were treated by six cycles at 3-week intervals of etoposide 120 mg/m2 i.v. on day 1 and orally on days 2-5, adriamycin 40 mg/m2 i.v. on day 1 and vincristine 1.4 mg/m2 i.v. on day 1. Tumour bed irradiation was administered to patients with limited disease after chemotherapy. In limited-disease and extensive-disease patients the median survival was 12 and 6 months respectively. The 2-year survival rate (life table) in limited-disease patients was 26%. Treatment morbidity was low. A prospective randomised trial is being undertaken to further evaluate the role of oral etoposide in combination chemotherapy.
|
Authors | R P Abratt, P A Willcox, R H Hewitson |
Journal | Cancer chemotherapy and pharmacology
(Cancer Chemother Pharmacol)
Vol. 20
Issue 1
Pg. 83-4
( 1987)
ISSN: 0344-5704 [Print] Germany |
PMID | 3040288
(Publication Type: Journal Article)
|
Chemical References |
- Vincristine
- Etoposide
- Doxorubicin
|
Topics |
- Adult
- Aged
- Carcinoma, Small Cell
(drug therapy, radiotherapy)
- Doxorubicin
(therapeutic use)
- Drug Administration Schedule
- Etoposide
(therapeutic use)
- Female
- Humans
- Lung Neoplasms
(drug therapy, radiotherapy)
- Male
- Middle Aged
- Vincristine
(therapeutic use)
|